Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Gilead Says 11% of Prior Non-Responders Cured in Hepatitis Trial

Gilead Sciences Inc.’s experimental hepatitis C drug cleared the virus in 11 percent of patients who hadn’t responded to prior treatment, the company said today.

A combination of Gilead’s 7977 drug and the antiviral ribavirin cleared 1 out of 9 so-called “null responder” patients with the most common genotype 1 form of the virus four weeks after ending treatment, the Foster City, California-based company said today in a poster at the European Association for the Study of Liver meeting in Barcelona. The cure rate compares with 88 percent of patients who had never been treated before.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.